We used the well-known effector of CYP3A4 ANF [27,44], the non-selective tyrosine kinase inhibitor Gefitinib, used in cancer therapy [60], and the anti-inflammatory natural compound Schisandrin A [61]. The gene discussed is CYP3A4; the disease is cancer.